Loading
Loading
Research Overview
Proapoptotic peptide that selectively targets vasculature supplying white adipose tissue by binding prohibitin on fat-cell blood vessels, inducing targeted apoptosis of the adipose vasculature and reducing fat mass in preclinical models.
Adipotide consists of two functional domains: a targeting sequence binding to PROHIBITIN on white adipose tissue endothelial cells, and a pro-apoptotic KLAKLAK domain. Preclinical research has used this compound to study the consequences of selectively inducing apoptosis in the blood vessel cells supplying white adipose tissue in animal models.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, adipotide (ftpp) peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Adipotide (FTPP) Peptide research is most relevant to protocols examining:
Novel fat loss mechanism research targeting adipose vasculature
Prohibitin biology and white adipose tissue studies
Researchers comparing targeted apoptotic fat reduction vs metabolic approaches
Preclinical obesity model investigations
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Proapoptotic peptide that selectively targets vasculature supplying white adipose tissue by binding prohibitin on fat-cell blood vessels, inducing targeted apoptosis of the adipose vasculature and reducing fat mass in preclinical models.
| Parameter | Value |
|---|---|
| Dose range | Under investigation |
| Schedule | Daily |
| Route | Subcutaneous |
| Half-life | ~Hours |
experimental compound
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.